John H. Rex, M.D.

Associate Professor Medicine

Division of Infectious Diseases, Department of Internal Medicine,

Center for the Study of Emerging and Reemerging Pathogens, 

University of Texas Medical School, Houston, Texas

Mailing address:

AstraZeneca, Alderley House, Alderley Park

Macclesfield Cheshire, SK10 4TF, United Kingdom

Email: John.Rex@astrazeneca.com

            Dr. Rex received his M.D. from Baylor College of Medicine.  He performed his residency at the Stanford University Hospitals & Clinics and fellowship at the National Institute of Allergy and Infectious Diseases

            Dr. Rex's work is focused in three areas. First, he participated in a variety of clinical trials that investigate the utility of new antifungal agents in human infection.  His work in this area has focused primarily on invasive fungal infections of the critically-ill non-neutropenic adult.

            Second, Dr. Rex's laboratory is involved in a variety of studies on the technical aspects of in vitro susceptibility testing.  He is a member of the National Committee for Clinical Laboratory Standards' Antifungal Susceptibility Testing Subcommittee.  Through the work done in his laboratory with this committee, he has had the opportunity to participate in the development of the M27 and M38 documents on susceptibility testing of yeasts and moulds, respectively.

            Third, Dr. Rex's laboratory uses animal models of invasive fungal infections to investigate better ways to treat these infections in humans.  He and collogues investigate both new drugs and new ways to better use old drugs.  These studies are often directly tied to better understanding of ways to use in vitro susceptibility testing to predict response to infection.